Corcept Therapeutics Incorporated

Nxera Pharma UK Limited

Abbvie Inc.

Mark Mills

Andrew William Phillips

Hazel Joan Hunt

Lorna Duffy

Thomas Hornsby

Morgan Jouanneau

Miles Stuart Congreve

Giles Albert Brown

Benjamin Gerald Tehan

John Andrew Christopher

Sarah Joanne Bucknell

Nigel Alan Swain

Ian Strutt

Anil Patel

Jon-Paul Ward

Anne Mary Stephenson

Anthony Mastracchio

Geraint Jones

Andrew James Smith

Bohdan Waszkowycz

Puneet Kumar

Angus Morrison

Euan Fordyce

Jonathan Gillespie

Angelo Pugliese

The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Orexin 1 receptor antagonists

The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Oxexin 1 receptor antagonists

The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.

Quaternary indazole glucocorticoid receptor antagonists

The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.

Bicyclic indazole glucocorticoid receptor antagonists

Provided are piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.

Piperazine indazole glucocorticoid receptor antagonists

The present disclosure provides for compounds of the general Formula (I)

Thiazolo[5,4-b]pyridine MALT-1 inhibitors

Growing community of inventors

Nottingham, United Kingdom

Mark Mills